FDA push­es back de­ci­sion on Zevra’s drug; Re­vance to raise $100M

Plus, news about Io­vance Bio­ther­a­peu­tics, Nek­tar Ther­a­peu­tics, Hei­del­berg Phar­ma, Vivory­on Ther­a­peu­tics and Ab­sci:

FDA de­lays de­ci­sion on Zevra Ther­a­peu­tics’ rare dis­ease drug: The FDA will now de­cide whether to ap­prove Zevra’s treat­ment for a lyso­so­mal stor­age dis­or­der called Nie­mann-Pick dis­ease type C by Sept. 21, three months lat­er than an ini­tial de­ci­sion dead­line in June. Zevra had sub­mit­ted ad­di­tion­al in­for­ma­tion for ari­mo­clo­mol, which is a small mol­e­cule med­i­cine de­liv­ered three times a day. The com­pa­ny’s stock $ZVRA was down about 11% on Mon­day morn­ing. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER